Phase 3 Study Comparing the Efficacy and Safety of Reloading Prasugrel and Clopidogrel in Acute Coronary Syndrome Patients With CYP2C19 Polymorphism Who Undergo Percutaneous Coronary Intervention.
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Prasugrel (Primary) ; Clopidogrel
- Indications Acute coronary syndromes; Thrombosis
- Focus Pharmacodynamics
- Acronyms PRAISE-GENE
- 28 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.
- 28 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated